Form 8-K · Current Report · Filed 2024-10-03
Illumina Announces Departure of General Counsel and Secretary
Illumina, Inc. announced on October 3, 2024, that Charles Dadswell, its General Counsel and Secretary, will leave the company. He will serve in an advisory role until March 31, 2025, and will receive certain benefits and a lump-sum payment upon completion of his advisory services. Scott Davies will serve as Interim General Counsel and Secretary.
- Filer
- Illumina, Inc. ILMN · NASDAQ
- Filed
- Accession
- 0000950157-24-001364
- CIK
- 0001110803
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Financial Statements and Exhibits
Market reaction
Close before filing
$139.02
Next session
+1.7%
Since filing
+47.5%
Latest close
$205.10
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ILMN reporting the same item, with the next session's move:
Exhibits (2)
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Never miss another ILMN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.